Continuous low-dose anti-angiogenic/metronomic chemotherapy: From the research laboratory into the oncology clinic

Annals of Oncology

Volumn 13, Issue 1, 2002, Pages 12-15

  Kerbel, R S ^a,b,c   Klement, G ^a,b,c   Pritchard, K I ^a,b,c   Kamen, B ^a,b,c  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^b DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^c ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CETUXIMAB; CYCLOOXYGENASE 2 INHIBITOR; CYCLOPHOSPHAMIDE; GEFITINIB; METHOTREXATE; NEUTRALIZING ANTIBODY; TAXANE DERIVATIVE; THALIDOMIDE; TRASTUZUMAB; VASCULOTROPIN ANTIBODY;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADVANCED CANCER; ALOPECIA; ANIMAL EXPERIMENT; ANIMAL MODEL; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER CENTER; CANCER REGRESSION; CANCER RESEARCH; COLITIS; COST EFFECTIVENESS ANALYSIS; DOSE RESPONSE; DRUG COST; EDITORIAL; FEBRILE NEUTROPENIA; FEMALE; GLIOMA; HUMAN; LABORATORY; LEUKOPENIA; METASTASIS; MOUSE; MUCOSA INFLAMMATION; NAUSEA AND VOMITING; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL;

EID: 0036225444     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdf093     Document Type: Editorial

References (26)

1. Heterogeneity of angiogenesis and blood vessel maturation in human tumors: Implications for antiangiogenic tumor therapies
2. Inhibition of angiogenesis by the antineoplastic agents mitoxantrone and bisantrene
3. Redefining the target: Chemotherapeutics as antiangiogenics
4. The onset and extent of genomic instability in sporadic colorectal tumor progression
5. Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents
6. Cancer: Looking outside the genome
7. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer
8. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer
9. Less is more, regularly: Metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice
10. High-time chemotherapy or high time for low dose
11. Antiangiogenic scheduling of lower dose cancer chemotherapy
12. Weekly taxol (T) in patients who had relapsed or remained stable with T in a 21 day schedule
13. Docetaxel administered on a weekly basis for metastatic breast cancer
14. Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer
15. Docetaxel (Taxotere) administered in weekly schedules
16. Frequent, moderate-dose cyclophosphamide administration improves the efficacy of cytochrome P-450/cytochrome P-450 reductase-based cancer gene therapy
17. Six months of maintenance chemotherapy after intensified treatment for acute lymphoblastic leukemia of childhood
18. Low dose oral methotrexate and cyclophosphamide in metastatic breast cancer: Antitumor activity and correlation with vascular endothelial growth factor levels
19. Angiogenesis research. Cancer drugs found to work in new way
20. Chemotherapeutic drugs-more really is not better
21. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity
22. Low-dose chemotherapy combined with an antiangiogenic drug reduces human glioma growth in vivo
23. Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrug-resistant human breast cancer xenograft
24. A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer
25. Cyclooxygenase inhibitors suppress angiogenesis and reduce tumor growth in vivo
26. Antiangiogenic and anti-tumor activities of cyclooxygenase-2 inhibitors